m+Medelevator.RU
← Поиск публикаций
Biomedical optics express · 2025

In vivo quantification of viscoelastic property alterations in oral submucous fibrosis using optical coherence elastography.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Han Xiao, Zhang Yubao, Luo Jiahui, Zhang Shijian, Lin Chuanqi, Zhang Qin, He Xingdao

Аннотация

Quantitative analysis of viscoelastic alterations in oral submucous fibrosis (OSF) provides crucial insights for monitoring disease progression and preventing malignant transformation. We developed a piezoelectric-based optical coherence elastography (OCE) system for real-time, in vivo quantitative assessment of OSF progression. In our experimental model, sixteen rats were systematically divided into four groups representing progressive fibrosis stages. Phase-sensitive OCE measurements captured distinctive elastic wave propagation patterns across all experimental groups. Comprehensive analysis of phase velocity dispersion curves and wave attenuation enabled the extraction of quantitative viscoelastic parameters that reflect fundamental tissue changes. Results demonstrated significant biomechanical alterations with disease progression, most notably a nearly four-fold increase in Young's modulus from normal tissue (32.6 ± 3.9 kPa) to severe fibrosis (121.1 ± 9.9 kPa), accompanied by more than doubled viscosity coefficients (0.52 ± 0.06 Pa·s to 1.27 ± 0.15 Pa·s). Particularly significant was the loss factor (G"/G') pattern, which exhibited a non-monotonic trend-decreasing from 0.30 in control specimens to 0.18 in moderate fibrosis groups before slightly increasing to 0.20 in severe fibrosis groups. The viscoelastic parameters quantified by OCE may facilitate more precise staging of OSF and potentially provide early indicators for assessing progression risk toward malignancy.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты